Tick-borne viral encephalitis, unspecified
ICD-10 A83.9 is a billable code used to indicate a diagnosis of tick-borne viral encephalitis, unspecified.
Tick-borne viral encephalitis (TBE) is a viral infection that affects the central nervous system (CNS) and is transmitted primarily through the bite of infected ticks. The disease is caused by the tick-borne encephalitis virus (TBEV), which can lead to severe neurological complications, including encephalitis, meningitis, and myelitis. Symptoms typically include fever, headache, fatigue, and neurological deficits, which may progress to seizures, confusion, and coma in severe cases. The clinical presentation can vary widely, with some patients experiencing mild flu-like symptoms while others develop serious CNS involvement. Diagnosis is primarily based on clinical presentation, serological testing for TBEV antibodies, and sometimes PCR testing of cerebrospinal fluid (CSF). Vaccination against TBE is available and recommended for individuals at high risk, such as those living in or traveling to endemic areas. The unspecified designation indicates that the specific type or severity of the encephalitis is not documented, which may complicate treatment and management decisions.
Detailed clinical notes on symptoms, laboratory results, and vaccination history.
Patients presenting with neurological symptoms after tick exposure.
Ensure thorough documentation of travel history and tick exposure.
Neurological examination findings, imaging results, and treatment plans.
Patients with acute neurological deficits and suspected viral encephalitis.
Document any differential diagnoses considered and ruled out.
Used when serological testing is performed to confirm TBE.
Document the reason for testing and results.
Infectious disease specialists should ensure comprehensive testing.
Common symptoms include fever, headache, fatigue, and neurological signs such as confusion, seizures, and altered consciousness.
Diagnosis is based on clinical symptoms, serological testing for TBEV antibodies, and PCR testing of cerebrospinal fluid.
Yes, there is a vaccine available for individuals at high risk, particularly those living in or traveling to endemic areas.
